1 / 27

Non-pharmacological approach to comorbidities in COPD

Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà dell’autore e fornito come supporto didattico per uso personale. Non-pharmacological approach to comorbidities in COPD.

shanon
Download Presentation

Non-pharmacological approach to comorbidities in COPD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra.Le ricordiamo che questo materiale è di proprietà dell’autore e fornito come supporto didattico per uso personale.

  2. Non-pharmacological approach to comorbidities in COPD Thierry.troosters@med.kuleuven.be

  3. Outline • Inactivity driving morbidity in COPD • Preventing morbidity by remaining active • Treating morbidity by becoming active

  4. Functional status in COPD Predicting Functional status GOLD IV Mean 289 GOLD III Mean 365 GOLD II Mean 405 R 0.34 p < 0.01 (ECLIPSE) R 0.30 p < 0.01 (Leuven) 60 50 40 Percentage of patients (3x100%) 30 20 10 0-30 90-150 570-630 330-390 450-510 210-270 Agusti Respir Res 2010 UZ Leuven Rehab d-base 2010

  5. Functional status in COPD Predicting Functional status R 0.53 p < 0.01 (Leuven) Factors associated to 6MWD N=496 partial R2 p QF (Nm.kg-1) 0.21 0.001 FEV1 (%pred) 0.11 0.001 PImax (cmH2O) 0.01 0.01 UZ Leuven Rehab d-base 2010

  6. Functional status in COPD N=279 N=159

  7. Long term inactivity, driving morbidity Physical inactivity drives morbidity -36% -43% moderate PA Troosters Respir Med 2010 Watz AJRCCM 2008

  8. Long term inactivity, driving morbidity KU-Leuven Rainbow study (Undiagnosed COPD )

  9. Long term inactivity, driving morbidity KU-Leuven Rainbow study (Undiagnosed COPD ) Amount and Intensity of physical activity are important to maintain health Physical activity should be considered as a ‘vital sign’ Haskell Circulation 2007 CDC Physical activity plan March 2010

  10. Inactivity a source of comorbidity? COPD CF

  11. Inactivity a source of comorbidity? COPD Wagner Respirology 2006

  12. Inactivity and Morbidity • Deconditioning • Cardiovascular morbidity • Insulin resistance • Cancer (Colon/Breast/Lung) • Arterial Hypertension • Bone and joint disease (Osteoporosis Arthritis) • Depression

  13. Inactivity and Morbidity Hypertens. Gastro-Int. Osteopor. Diabetes Arthritis Cardiac Cancer Psych Lipids Comorbidity (%) 36 22 28 - 70 - - - - 32 Van Manen J Clin Epidemiol 2001 Mapel Arch Intern Med 2000 Soriano Chest 2005 Sidney Chest 2005 Walsh ATS 2006 13 65 22 18 50 23 45 - 18 52 5 12 - 2 16 - - - 9 16 9 17 10 - 38 15 32 26 - 62 6 18 4 - 4 Chatila PATS 2008

  14. Comorbidity in COPD: physical (in)-activity COPD Age, gender, socialsuport, socioeconomic state, educational level Symptoms (Dyspnea) Barriers (symptoms) Airflow obstruction Dynamic hyperinflation Anxiety Physical (in-)activity (behavior) Exercise capacity Self-efficacy Health beliefs COMORBIDITY Mental state Muscle dysfunction Endocrine dysfunction Hematological abnormalities Cardiovascular morbidity Osteoporosis Steroids Exacerbations Sleep-disordered Breathing Steroids Oxidative stress Exacerbations Inflammation Exacerbations Pulmonary hyertension Inflammation Hypoxia Mortality

  15. Preventing morbidity by PA? • No long term prospective data in COPD • Epidemiological suggestions • Data in other diseases (e.g. diabetes)

  16. Preventing morbidity by PA? 1.0 Tio 14.9% Control 16.5% 0.75 SFC12.6% Placebo 15.2% 0.50 Mortality (Probability Survival) High Average Low 0.25 Very Low Very low: Mainly sitting work, no PA in leisure time Low: < 2h/week low intensity physical activity 0.0 0 5 10 15 20 Time (Years) Garcia-Aymerich Thorax 2006

  17. Preventing morbidity by PA? All groups received standard package of guidelines regarding healthy life style (written and annual session of 30') Intensive life style = 16 face to face sessions followed by monthly session Knowler NEJM 2002

  18. FB - R (n=18) UC - R (n=17) ± ± ± ± ± ± 67 112 63 17 20 8 62 114 61 14 14 9 FEV1 TLC Age Preventing morbidity by PA? How could this be achieved in COPD? • Raise awareness in milder patients • Assess Physical activity • Provide feedback on PA levels • Discuss this with your patients Hospes Patient Educ Counsel 2008

  19. Treating co-morbidity by exercise training? Exercise tolerance: Weighted mean difference and IQR Adapted fromTroosters AJRCCM 2005

  20. Treating co-morbidity by exercise training? Rehabilitation has a clear effect on • HRQoL and symptoms • Exercise tolerance • Skeletal muscle weakness • Depressed mood status • Exacerbations

  21. Rehabilitation has the potential to improve PA Weighted mean +17% Troosters Eur Respir Rev 2010

  22. Rehabilitation impact on comorbidity? Exercise training and Arterial Stiffness, marker of CV risk N=10 4 weeks of PR 5d/week Endurance training * Vivodtzef Chest 2010

  23. Rehabilitation impact on comorbidity? Exercise training and Arterial Stiffness, marker of CV risk * Vivodtzef Chest 2010

  24. Rehabilitation impact on comorbidity? Heart Transplantation Lung Transplantation N=8/8 N=6/10 ** ** L2-L3 Bone mineral density (% change vs pre TX) Braith Transplantation 2006 Mitchel Transplantation 2003

  25. Do co-morbidities complicate rehabilitation? Crisafulli ERJ 2010

  26. Do co-morbidities complicate rehabilitation? Proportion of patients with clinical benefit Exercise training yields significant effects, also in patients with comorbidity Crisafulli ERJ 2010

  27. Summary • Comorbidity in COPD is at least partially driven by physical inactivity • BESIDES SMOKING CESSATION, early interventions aiming at keeping patients active could potentially prevent comorbidity • Exercise training as a stimulus may treat some comorbidity (muscle weakness, vascular, type II diabetes, osteoporosis, depression) • Patients with comorbidities are good candidates for exercise training

More Related